Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
The Cleveland Clinic
Study ID
NCT06694558
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Kidney Disease(CKD)
  • Type 1 Diabetes (T1D)

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Study Details

This is a cross-sectional study in patients with Type 1 diabetes (TID) and chronic kidney disease (CKD) to test if time in range (TIR) affects the degree of hyperglycemia required for monocyte activation, podocyte injury, and assess if monocyte activation is attenuated by glucagon-like peptide (GLP-1) agonist treatment ex vivo.

Key Dates

Start date
Mar 1, 2025
Status verified
Jun 2025
Primary completion
Dec 30, 2025
Completion
Jul 1, 2026

Study Design

Enrollment
60 participants (estimated)

Arms

  • Arm: Patients with Type 1 Diabetes
    Patients with Type 1 Diabetes with or without chronic kidney disease

Primary Outcome Measure

Number of subjects with proinflammatory monocytes by flow cytometry, higher ER stress, and cytokine levels after monocyte exposure to hyperglycemia compared to euglycemia for 6 hours. [ Time Frame: monocyte response to varying glycemic exposure after 6 hrs ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Cleveland ClinicClevelandOhio44195
Andrea Debs
[email protected]
216-445-8354

Find similar trials in Cleveland, OH

By research site
Cleveland Clinic· Cleveland, OH

Related Studies